Delaware
|
06-1123096
|
(State or other jurisdiction of
|
(I.R.S. employer
|
incorporation or organization)
|
identification no.)
|
Large Accelerated Filer
o
|
Accelerated Filer
o
|
Non-Accelerated Filer
o
|
Smaller Reporting Company
x
|
PART I
|
Financial Information
|
Page No.
|
Item 1
|
Financial Statements (Unaudited)
|
|
Condensed Consolidated Balance Sheets as of June 30, 2009 and December 31, 2008
|
3
|
|
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2009 and 2008
|
5
|
|
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2009 and 2008
|
6
|
|
Notes to Condensed Consolidated Financial Statements
|
7
|
|
Item 2
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
11
|
Item 3
|
Quantitative and Qualitative Disclosures about Market Risk
|
16
|
Item 4
|
Controls and Procedures
|
16
|
PART II
|
Other Information
|
|
Item 1
|
Legal Proceedings
|
17
|
Item 4
|
Submission of Matters to a Vote of Security Holders
|
18
|
Item 5
|
Other Information
|
19
|
Item 6
|
Exhibits
|
20
|
Signatures
|
21
|
Assets
|
June 30,
|
December 31,
|
||||||
2009
|
2008
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 814,960 | $ | 1,082,619 | ||||
Accounts receivable, net of allowance
|
4,368,032 | 3,681,355 | ||||||
Other receivables
|
— | 715,769 | ||||||
Recoverable income taxes
|
215,762 | 101,185 | ||||||
Inventories
|
9,284,424 | 9,786,538 | ||||||
Deferred income taxes
|
696,439 | 791,493 | ||||||
Other current assets
|
494,030 | 411,938 | ||||||
Total current assets
|
15,873,647 | 16,570,897 | ||||||
Property and equipment:
|
||||||||
Leasehold improvements
|
303,710 | 281,612 | ||||||
Property and equipment
|
5,445,598 | 5,326,735 | ||||||
Equipment at customers
|
1,171,217 | 1,132,422 | ||||||
|
|
|
||||||
6,920,525 | 6,740,769 | |||||||
Accumulated depreciation and amortization
|
(4,560,719 | ) | (4,013,900 | ) | ||||
2,359,806 | 2,726,869 | |||||||
Other assets (net):
|
||||||||
Intangible and other assets
|
734,934 | 757,378 | ||||||
Goodwill
|
3,379,021 | 3,379,021 | ||||||
Deferred income taxes
|
1,155,012 | 250,370 | ||||||
|
||||||||
5,268,967 | 4,386,769 | |||||||
|
|
|||||||
Total assets
|
$ | 23,502,420 | $ | 23,684,535 |
June 30,
|
December 31,
|
|||||||
Liabilities and Stockholders’ Equity
|
2009
|
2008
|
||||||
Current liabilities:
|
||||||||
Current portion of long-term debt
|
$ | 632,931 | $ | 614,067 | ||||
Line-of-credit
|
3,123,277 | 1,994,008 | ||||||
Notes payable
|
202,713 | — | ||||||
Accounts payable
|
2,415,996 | 2,307,675 | ||||||
Accrued expenses
|
1,110,918 | 835,868 | ||||||
Total current liabilities
|
7,485,835 | 5,751,618 | ||||||
Long-term debt, less current portion
|
1,386,855 | 1,708,493 | ||||||
Deferred gain on sale and leaseback of property
|
1,101,382 | 1,168,701 | ||||||
Income taxes payable
|
161,375 | 155,875 | ||||||
Stockholders’ equity:
|
||||||||
Series A cumulative convertible preferred stock, $.001
|
||||||||
par value per share, 1,000,000 shares authorized, no
|
||||||||
shares issued or outstanding
|
— | — | ||||||
Common stock, $.004 par value per share, 40,000,000
|
||||||||
shares authorized, 11,605,189 and 11,419,535 shares
|
||||||||
issued at June 30, 2009 and December 31, 2008,
|
||||||||
respectively, including shares held in treasury
|
46,421 | 45,675 | ||||||
Common stock held in treasury, at cost - 86,000 shares
|
(101,480 | ) | (101,480 | ) | ||||
Additional paid-in capital
|
7,626,244 | 7,423,340 | ||||||
Retained earnings
|
5,795,788 | 7,532,313 | ||||||
Total stockholders’ equity
|
13,366,973 | 14,899,848 | ||||||
Total liabilities and stockholders’ equity
|
$ | 23,502,420 | $ | 23,684,535 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30, | June 30, | |||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Net sales
|
$ | 8,568,115 | $ | 10,542,919 | $ | 16,973,939 | $ | 19,504,470 | ||||||||
Cost of sales
|
5,975,792 | 7,051,041 | 11,916,487 | 13,332,437 | ||||||||||||
Gross profit
|
2,592,323 | 3,491,878 | 5,057,452 | 6,172,033 | ||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
577,843 | 466,639 | 1,204,038 | 977,965 | ||||||||||||
Selling, general and administrative
|
3,178,141 | 3,052,337 | 6,389,269 | 6,073,210 | ||||||||||||
3,755,984 | 3,518,976 | 7,593,307 | 7,051,175 | |||||||||||||
Operating loss
|
(1,163,661 | ) | (27,098 | ) | (2,535,855 | ) | (879,142 | ) | ||||||||
Interest expense, net
|
62,875 | 71,160 | 112,519 | 143,257 | ||||||||||||
Loss before income taxes
|
(1,226,536 | ) | (98,258 | ) | (2,648,374 | ) | (1,022,399 | ) | ||||||||
Income tax benefit
|
(392,878 | ) | (66,250 | ) | (911,848 | ) | (460,500 | ) | ||||||||
Net loss
|
$ | (833,658 | ) | $ | (32,008 | ) | $ | (1,736,526 | ) | $ | (561,899 | ) | ||||
Loss per common share:
|
||||||||||||||||
Basic
|
$ | (0.07 | ) | $ | 0.00 | $ | (0.15 | ) | $ | (0.05 | ) | |||||
Diluted
|
$ | (0.07 | ) | $ | 0.00 | $ | (0.15 | ) | $ | (0.05 | ) | |||||
Weighted average number of
|
||||||||||||||||
common shares outstanding:
|
||||||||||||||||
Basic
|
11,224,829 | 10,989,920 | 11,218,419 | 10,885,606 | ||||||||||||
Diluted
|
11,224,829 | 10,989,920 | 11,218,419 | 10,885,606 | ||||||||||||
Six Months Ended
|
||||||||
June 30,
|
||||||||
|
2009
|
2008
|
||||||
OPERATING ACTIVITIES:
|
||||||||
Net loss
|
$ | (1,736,526 | ) | $ | (561,899 | ) | ||
Adjustments to reconcile net loss to
|
||||||||
net cash (used) provided by operating activities:
|
||||||||
Depreciation and amortization
|
628,807 | 573,779 | ||||||
Deferred income taxes
|
(809,588 | ) | (362,112 | ) | ||||
Non-cash stock compensation
|
166,417 | 231,315 | ||||||
Amortization of deferred gain on sale and leaseback of property
|
(67,319 | ) | (67,319 | ) | ||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(686,677 | ) | 462,984 | |||||
Other receivable
|
715,769 | — | ||||||
Inventories
|
502,114 | (1,106,968 | ) | |||||
Other current assets
|
(82,092 | ) | (146,505 | ) | ||||
Recoverable income taxes, net
|
(114,577 | ) | 55,536 | |||||
Accounts payable and accrued expenses
|
383,372 | 1,250,683 | ||||||
Income taxes payable
|
5,500 | 5,500 | ||||||
Net cash (used) provided by operating activities
|
(1,094,800 | ) | 334,994 | |||||
INVESTING ACTIVITIES:
|
||||||||
Expenditures for property and equipment
|
(179,756 | ) | (920,625 | ) | ||||
Purchase of intangible assets
|
(59,544 | ) | (353,081 | ) | ||||
Net cash used by investing activities
|
(239,300 | ) | ( 1,273,706 | ) | ||||
FINANCING ACTIVITIES:
|
||||||||
Repayments of long-term debt
|
(302,774 | ) | (284,335 | ) | ||||
Proceeds from notes payable
|
228,052 | 298,704 | ||||||
Repayments of notes payable
|
(25,339 | ) | (209,736 | ) | ||||
Borrowings from line-of-credit, net
|
1,129,269 | 295,576 | ||||||
Tax effect from vesting of restricted stock
|
— | (2,949 | ) | |||||
Proceeds from issuance of common stock
|
37,233 | 1,085,523 | ||||||
Net cash provided by financing activities
|
1,066,441 | 1,182,783 | ||||||
Change in cash and cash equivalents
|
(267,659 | ) | 244,071 | |||||
Cash and cash equivalents, beginning of period
|
1,082,619 | 666,722 | ||||||
Cash and cash equivalents, end of period
|
$ | 814,960 | $ | 910,793 | ||||
Supplemental Disclosures of Cash Flow Information:
|
||||||||
Cash paid during the period for interest
|
$ | 109,616 | $ | 143,053 | ||||
Cash paid (collected) during the period for income taxes, net
|
$ | 6,818 | $ | (156,475 | ) |
(1)
|
The Company
|
(2)
|
Basis of Presentation
|
(3)
|
Inventories, Property and Equipment, Intangible Assets and Goodwill
|
June 30,
|
December 31,
|
|||||||
2009
|
2008
|
|||||||
Raw materials
|
$ | 7,298,713 | $ | 7,560,332 | ||||
Work-in-process
|
71,784 | 24,560 | ||||||
Finished goods
|
1,913,927 | 2,201,646 | ||||||
$ | 9,284,424 | $ | 9,786,538 |
(4)
|
Principal Products and Services
|
·
|
Critical care monitoring products – includes sales of the FORE-SIGHT® cerebral monitor and accessories.
|
·
|
Bedside monitoring products – includes sales of cardio-respiratory monitors and accessories used to monitor apnea in home-based and hospital settings; the Company’s dual platform of vital signs monitors and accessories incorporating various combinations of measurement parameters for both human and veterinary use including pulse oximetry, electro-cardiography,
temperature, non-invasive blood pressure, and capnography; co-branded products developed and manufactured by Analogic Corporation including vital signs monitors utilizing parameters as described above and additionally monitors which measure non-invasive cardiac output and hemodynamic status, and fetalgard monitors.
|
·
|
Blood pressure measurement technology – includes sales to Original Equipment Manufacturers (“OEM”) of the Company’s proprietary non-invasive blood pressure modules (MAXNIBP®), blood pressure cuffs and accessories for the OEM market and related license fees.
|
·
|
Supplies and service – includes sales of blood pressure cuffs and rapid infusor cuffs, neonatal intensive care supplies including electrodes and skin temperature probes, and service repair revenues.
|
(5)
|
Loss per Common Share
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Weighted average shares outstanding, net
of restricted shares – used to compute basic loss per share
|
11,224,829 | 10,989,920 | 11,218,419 | 10,885,606 | ||||||||||||
Dilutive effect of restricted shares, and outstanding warrants and options
|
— | — | — | — | ||||||||||||
Weighted average shares of dilutive Securities outstanding – used to compute diluted loss per share
|
11,224,829 | 10,989,920 | 11,218,419 | 10,885,606 |
(6)
|
Stock-Based Compensation
|
Aggregate
|
Weighted-Average
|
|||||
Option
|
Weighted-Average
|
Intrinsic
|
Contractual Life
|
|||
Shares
|
Exercise Price
|
Value (1)
|
Remaining in Years
|
|||
Outstanding at December 31, 2008
|
590,125
|
$ 2.43
|
$ 219,264
|
|||
Granted
|
5,000
|
1.30
|
||||
Cancelled
|
(1,000)
|
1.50
|
||||
Exercised
|
—
|
—
|
||||
Outstanding at June 30, 2009
|
594,125
|
$ 2.42
|
$ 206,626
|
5.63
|
||
Exercisable at June 30, 2009
|
477,457
|
$ 2.09
|
$ 203,726
|
4.78
|
Six Months Ended
|
|||
June 30, 2009
|
June 30, 2008
|
||
Weighted-average expected stock-price volatility
|
82.9%
|
63.4%
|
|
Weighted-average expected option life
|
4.2 years
|
4.2 years
|
|
Average risk-free interest rate
|
2.93%
|
3.81%
|
|
Average dividend yield
|
0.0%
|
0.0%
|
(7)
|
Financing Arrangements
|
(8)
|
Income Taxes
|
(9)
|
Contingencies
|
(10)
|
Fair Value of Financial Instruments
|
(11)
|
Recent Accounting Pronouncements
|
Three Months Ended
|
Three Months Ended
|
Increase/
|
||||||||||
($000’s)
|
June 30, 2009
|
June 30, 2008
|
(Decrease)
|
|||||||||
Bedside Monitoring Products
|
$ | 3,068 | $ | 3,900 | $ | (832 | ) | |||||
Critical Care Monitoring Products
|
982 | 377 | 605 | |||||||||
Blood Pressure Measurement Technology
|
1,476 | 2,204 | (728 | ) | ||||||||
Supplies and Service
|
3,042 | 4,062 | (1,020 | ) | ||||||||
$ | 8,568 | $ | 10,543 | $ | (1,975 | ) | ||||||
Domestic Sales
|
5,589 | 7,730 | (2,141 | ) | ||||||||
International Sales
|
2,979 | 2,813 | 166 | |||||||||
$ | 8,568 | $ | 10,543 | $ | (1,975 | ) |
Six Months Ended
|
Six Months Ended
|
Increase/
|
||||||||||
($000’s)
|
June 30, 2009
|
June 30, 2008
|
(Decrease)
|
|||||||||
Bedside Monitoring Products
|
$ | 5,644 | $ | 7,408 | $ | (1,764 | ) | |||||
Critical Care Monitoring Products
|
1,867 | 650 | 1,217 | |||||||||
Blood Pressure Measurement Technology
|
2,959 | 3,563 | (604 | ) | ||||||||
Supplies and Service
|
6,504 | 7,883 | (1,379 | ) | ||||||||
$ | 16,974 | $ | 19,504 | $ | (2,530 | ) | ||||||
Domestic Sales
|
11,959 | 14,062 | (2,103 | ) | ||||||||
International Sales
|
5,015 | 5,442 | (427 | ) | ||||||||
$ | 16,974 | $ | 19,504 | $ | (2,530 | ) |
Nominee
|
For
|
Withheld
|
|
Jerome S. Baron
|
9,757,602
|
256,889
|
|
Lawrence S. Burstein
|
9,757,602
|
256,889
|
|
Evan Jones
|
9,914,140
|
100,351
|
|
Andrew E. Kersey
|
9,220,712
|
793,779
|
|
Louis P. Scheps
|
8,265,505
|
1,748,986
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
4,282,690
|
87,130
|
101,210
|
5,543,461
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
4,049,699
|
301,761
|
119,570
|
5,543,461
|
For
|
Against
|
Abstain
|
9,237,971
|
185,726
|
67,543
|
10.1
|
Employment Agreement dated August 10, 2009 between the Company and Andrew E. Kersey, President and Chief Executive Officer
|
10.2
|
Employment Agreement dated August 10, 2009 between the Company and Jeffery A. Baird, Chief Financial Officer
|
31.1
|
Certification pursuant to Rule 13a-14(a) of Andrew E. Kersey, President and Chief Executive Officer
|
31.2
|
Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief Financial Officer
|
32.1
|
Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report of Andrew E. Kersey, President and Chief Executive Officer and Jeffery A. Baird, Chief Financial Officer
|
|
|
|
||
/s/ Andrew E. Kersey
|
Date: August 12, 2009
|
|
||
By: Andrew E. Kersey
|
||||
President and Chief Executive Officer | ||||
|
|
|
||
|
||||
/s/ Jeffery A. Baird
|
Date: August 12, 2009
|
|
||
By: Jeffery A. Baird
|
||||
Chief Financial Officer |
Section 1.
|
Employment
|
Section 2.
|
Duties
|
Section 3.
|
Term of Employment
|
Section 4.
|
Salary
|
Section 5.
|
Bonus
|
Section 6.
|
Employee Benefits
|
Section 7.
|
Business Expenses
|
Section 8.
|
Vacations and Sick Leave
|
Section 9.
|
Termination
|
(i)
|
a reduction greater than five (5) percent in the aggregate in the Employee’s base salary or benefits, other than an across-the-board reduction affecting substantially all members of senior management;
|
(ii)
|
a material reduction in the Employee’s duties and significant responsibilities hereunder following the occurrence of a Change of Control, as defined in Section 10(b) hereof (not including reasonable changes in title or in corporate structure); or
|
(iii)
|
a material breach of this Agreement by the Company (which shall include a failure to make payments due hereunder);
|
(1)
|
Payment of the Severance Payments shall commence as of the Employee’s Separation from Service date, and shall continue thereafter in equal fixed installments over a six month period in accordance with the Company’s standard payroll procedures and normal payroll dates then in effect.
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee’s annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)), the excess shall not be paid as provided
in (1), above, but instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee’s Separation from Service date, without adjustment for the delay in payment.
|
(3)
|
In no event shall Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Severance Payments to a later date.
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately prior to his Separation from Service for the period of the COBRA coverage or six months, whichever
is shorter.
|
Section 10.
|
Change of Control
|
(1)
|
Payment of the Change of Control Severance Payments shall commence as of the Employee’s Separation from Service date, and shall continue thereafter in equal fixed installments over a one year period in accordance with the Company’s standard payroll procedures and normal payroll dates then in effect.
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee’s annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)), the excess shall not be paid as provided
in (1), above, but instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee’s Separation from Service date, without adjustment for the delay in payment.
|
(3)
|
In no event shall Change of Control Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Change of Control Severance Payments to a later date.
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately prior to his Separation from Service for the period of the COBRA coverage or one year, whichever
is shorter.
|
Section 11.
|
Agreement Not to Compete or Solicit
|
Section 12.
|
Confidential Information
|
|
The Employee agrees to keep secret and retain in the strictest confidence all confidential matters which relate to the Company or any affiliate of the Company, including, without limitation, customer lists, client lists, trade secrets, pricing policies and other business affairs of the Company and any affiliate of the Company learned by him from the Company or any such affiliate or otherwise before or after the date
of this Agreement, and not to disclose any such confidential matter to anyone outside the Company, or any of its affiliates, whether during or after his period of service with the Company, except as may be required in the course of a legal or governmental proceeding. Upon request by the Company, the Employee agrees to deliver promptly to the Company upon termination of his services for the Company, or at any time thereafter as the Company may request, all Company or affiliate memoranda, notes, records,
reports, manuals, drawings, designs, computer files in any media and other documents (and all copies thereof) relating to the Company’s or any affiliate’s business and all property of the Company or any affiliate associated therewith, which he may then possess or have under his control.
|
Section 13.
|
Remedy
|
Section 14.
|
Successors and Assigns
|
Section 15.
|
Governing Law
|
Section 16.
|
Entire Agreement
|
Section 17.
|
Waiver of Breach
|
Section 18.
|
Notices
|
Section 19.
|
Severability
|
Section 20.
|
Counterparts
|
Section 21.
|
Internal Revenue Code Section 409A Compliance.
|
(i)
|
“Separation from Service” means, generally, a termination of employment with the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A), and shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation
Section 1.409A-1(h)).
|
(ii)
|
“Involuntary Separation from Service” means a Separation from Service due to the independent exercise of the unilateral authority of the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A) to terminate the Employee’s employment, other than due to the Employee’s
implicit or explicit request, where the Employee was willing and able to continue employment with the Company. Notwithstanding the foregoing, a termination for Good Reason may constitute an Involuntary Separation from Service. Involuntary Separation from Service shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation Section 1.409A-1(n)).
|
The Company:
|
CAS MEDICAL SYSTEMS, INC.
By:
/s/
Jeffery A. Baird
Name: Jeffery A. Baird
Title: Chief Financial Officer
|
|
Employee:
|
/s/
Andrew E. Kersey
|
Andrew E. Kersey
|
Section 1.
|
Employment
|
Section 2.
|
Duties
|
Section 3.
|
Term of Employment
|
Section 4.
|
Salary
|
Section 5.
|
Bonus
|
Section 6.
|
Employee Benefits
|
Section 7.
|
Business Expenses
|
Section 8.
|
Vacations and Sick Leave
|
Section 9.
|
Termination
|
(i)
|
a reduction greater than five (5) percent in the aggregate in the Employee’s base salary or benefits, other than an across-the-board reduction affecting substantially all members of senior management;
|
(ii)
|
a material reduction in the Employee’s duties and significant responsibilities hereunder following the occurrence of a Change of Control, as defined in Section 10(b) hereof (not including reasonable changes in title or in corporate structure); or
|
(iii)
|
a material breach of this Agreement by the Company (which shall include a failure to make payments due hereunder);
|
(1)
|
Payment of the Severance Payments shall commence as of the Employee’s Separation from Service date, and shall continue thereafter in equal fixed installments over a six month period in accordance with the Company’s standard payroll procedures and normal payroll dates then in effect.
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee’s annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)), the excess shall not be paid as provided
in (1), above, but instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee’s Separation from Service date, without adjustment for the delay in payment.
|
(3)
|
In no event shall Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Severance Payments to a later date.
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately prior to his Separation from Service for the period of the COBRA coverage or six months, whichever
is shorter.
|
Section 10.
|
Change of Control
|
(1)
|
Payment of the Change of Control Severance Payments shall commence as of the Employee’s Separation from Service date, and shall continue thereafter in equal fixed installments over a one year period in accordance with the Company’s standard payroll procedures and normal payroll dates then in effect.
|
(2)
|
In the event the value of the Severance Payments shall exceed two times the lesser of the Employee’s annualized compensation or the maximum amount that may be taken into account for qualified plan purposes (in each case, as determined in accordance with Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)), the excess shall not be paid as provided
in (1), above, but instead shall be withheld and paid on the first regularly scheduled payroll date immediately following the date that is six months after the Employee’s Separation from Service date, without adjustment for the delay in payment.
|
(3)
|
In no event shall Change of Control Severance Payments be accelerated, nor shall the Employee be eligible to defer payment of Change of Control Severance Payments to a later date.
|
(4)
|
If COBRA continuation coverage under any Company healthcare plan is elected by the Employee, the Company shall provide such coverage on the same terms with respect to employee cost and employer subsidy as was being made available to the Employee immediately prior to his Separation from Service for the period of the COBRA coverage or one year, whichever
is shorter.
|
Section 11.
|
Agreement Not to Compete or Solicit
|
Section 12.
|
Confidential Information
|
|
The Employee agrees to keep secret and retain in the strictest confidence all confidential matters which relate to the Company or any affiliate of the Company, including, without limitation, customer lists, client lists, trade secrets, pricing policies and other business affairs of the Company and any affiliate of the Company learned by him from the Company or any such affiliate or otherwise before or after the date
of this Agreement, and not to disclose any such confidential matter to anyone outside the Company, or any of its affiliates, whether during or after his period of service with the Company, except as may be required in the course of a legal or governmental proceeding. Upon request by the Company, the Employee agrees to deliver promptly to the Company upon termination of his services for the Company, or at any time thereafter as the Company may request, all Company or affiliate memoranda, notes, records,
reports, manuals, drawings, designs, computer files in any media and other documents (and all copies thereof) relating to the Company’s or any affiliate’s business and all property of the Company or any affiliate associated therewith, which he may then possess or have under his control.
|
Section 13.
|
Remedy
|
Section 14.
|
Successors and Assigns
|
Section 15.
|
Governing Law
|
Section 16.
|
Entire Agreement
|
Section 17.
|
Waiver of Breach
|
Section 18.
|
Notices
|
Section 19.
|
Severability
|
Section 20.
|
Counterparts
|
Section 21.
|
Internal Revenue Code Section 409A Compliance.
|
(i)
|
“Separation from Service” means, generally, a termination of employment with the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A), and shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation
Section 1.409A-1(h)).
|
(ii)
|
“Involuntary Separation from Service” means a Separation from Service due to the independent exercise of the unilateral authority of the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A) to terminate the Employee’s employment, other than due to the Employee’s
implicit or explicit request, where the Employee was willing and able to continue employment with the Company. Notwithstanding the foregoing, a termination for Good Reason may constitute an Involuntary Separation from Service. Involuntary Separation from Service shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation Section 1.409A-1(n)).
|
The Company:
|
CAS MEDICAL SYSTEMS, INC.
By:
/s/
Andrew E. Kersey
Name: Andrew E. Kersey
Title: President and Chief Executive Officer
|
|
Employee:
|
/s/ Jeffery A. Baird
|
Jeffery A. Baird
|
a.
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;
|
|
b.
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
c.
|
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
d.
|
Disclosed
in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial
reporting; and
|
a.
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information;
and
|
b.
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant’s internal control
over financial reporting.
|
/s/ Andrew E. Kersey | Date: August 12, 2009 | |
Andrew E. Kersey | ||
President and Chief Executive Officer |
a.
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;
|
|
b.
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
c.
|
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
d.
|
Disclosed
in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial
reporting; and
|
a.
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information;
and
|
b.
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant’s internal control
over financial reporting.
|